Get started
Author

Connor Welch

Observed names: C. Welch, Welch, Connor
ORCID: 0000-0001-8453-2220
Observed ORCID: 0000-0001-8453-2220
OpenAlex ID: A5008494362
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
2023 · Rodrigo Entrialgo-Cadierno, Cristina Cueto-Ureña, et al. · Molecular Cancer · 27
PDF
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation
2024 · Ander Puyalto, María Rodríguez-Remírez, et al. · Molecular Cancer · 22
PDF
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
2023 · Irati Macaya, Marta Roman, et al. · Nature Communications · 22
PDF
Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer
2025 · Borja Ruiz-Fernández de Córdoba, Karmele Valencia, et al. · Signal Transduction and Targeted Therapy · 9
PDF
Correction: The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
2023 · Rodrigo Entrialgo‑Cadierno, Cristina Cueto‑Ureña, et al. · Molecular Cancer · 4
PDF
Blockade of the KRAS-FOSL1 axis elicits DNA damage repair deficiency exploitable with local and systemic genotoxic therapies
2026 · Silve Vicent, Connor Welch, et al. · Research Square
PDF
OA07.01 KRAS Pharmacological Blockade Elicits Tumoral Homologous Recombination Deficiency Exploitable With PARP Inhibitors
2025 · Connor Welch, Gabriela Novoa, et al. · Journal of Thoracic Oncology
239 (PB227): KRAS pharmacological blockade elicits tumoral homologous recombination deficiency exploitable with PARP inhibitors
2024 · C. Welch, G. Novoa, et al. · European Journal of Cancer
P1.06-02 Trametinib Plus ANTI-PD-1 Immunotherapy Impairs Tumor Growth and Increases Survival of Lung Cancer through ID1 Downregulation
2023 · A. Puyalto, M. Rodríguez-Remírez, et al. · Journal of Thoracic Oncology
PDF
2324P Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
2023 · A. Puyalto, M. Rodríguez-Remírez, et al. · Annals of Oncology
Effect of trametinib and anti-PD-1 combo on tumor growth and survival of KRAS-mutant lung cancer by ID1 downregulation.
2023 · Ander Puyalto Calvo, María Rodríguez-Remírez, et al. · Journal of Clinical Oncology
1727P Trametinib enhances PD-L1 expression in KRAS-mutant NSCLC via Id1 downregulation
2022 · A. Puyalto, M. Rodríguez-Remírez, et al. · Annals of Oncology
PDF
MA02.08 Trametinib Inhibition of MEK1 2 Upregulates PD-L1 Expression in KRAS-Mutant NSCLC Through ID1 Downregulation
2022 · A. Puyalto, M. Rodríguez-Remírez, et al. · Journal of Thoracic Oncology
Works count: 18
Citation count: 84
H-index: 4
I10-index: 3
Year
Topic
Type